ClinicalTrials.gg
RecruitingNCT06847867MIDASUpdated Jun 2, 2026

A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome

A Phase 2 interventional study of Momelotinib in Myelodysplastic Syndromes, sponsored by GlaxoSmithKline. Recruiting at 39 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 115 studies in Myelodysplastic Syndromes with a site in Spain — 19 open to participants now, 35 under way, 13 of them phase 3. Myelodysplastic Syndromes · Spain.

Planned enrollment
62nd of 101
80 · median 125
Started
2025
with 3 others
Phase 2
30 of 115
5 open now
Primary completion
2027-07
later than 20 of 34 live
Registered
113th of 115
by date
Lead sponsor
3 of 115
GlaxoSmithKline

Among the 115 studies in Myelodysplastic Syndromes with a site in Spain, this one is the 62nd largest by planned enrollment of the 101 interventional ones that give a count, is one of 4 that started in 2025, is one of 30 in phase 2, reaches primary completion later than 20 of the 34 other live ones, and was the 113th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

19 of the 115 studies in Myelodysplastic Syndromes with a site in Spain are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies in Myelodysplastic Syndromes with a site in Spain, or all of them as a file.
02

Study summary

The goal of this clinical trial is to determine if momelotinib is safe and effective for people with low-risk myelodysplastic syndromes (LR-MDS). The trial will also examine how the body processes the drug. Participants will receive different doses of momelotinib to find the best dose by evaluating effectiveness in improving red blood cell transfusion requirements and safety.

03

Conditions studied

  • Myelodysplastic Syndromes

Keywords

  • Momelotinib
  • Low-risk Myelodysplastic Syndrome
  • MIDAS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years or of legal age of consent in the jurisdiction in which the study is taking place, at the time of signing the form (ICF).
  • Documented diagnosis of MDS according to the World Health Organization classifications with an Revised International Prognostic Scoring System (IPSS-R) classification of very low, low, or intermediate risk disease, with an overall risk score ≤3.5 and bone marrow blasts \< 5%.
  • Received only one with either Erythropoiesis-stimulating agent (ESA) or luspatercept for LR-MDS-related anemia that is to therapy. Participants intolerant OR ineligible to prior ESA or luspatercept will fulfill this inclusion criterion provided the definition below is met.

    • Refractory to prior treatment: documentation of loss of erythroid (E) response or never achieved HI-E response as defined by the IWG 2018 criteria.
    • Intolerant to prior treatment: documentation of reasons for discontinuation of prior ESA containing regimen, either as single agent or combination (e.g., G-CSF) or luspatercept due to intolerance or adverse event.
    • ESA ineligible: low chance of response to ESA based on endogenous serum erythropoietin level > 200 U/L for participants not previously treated with ESAs.
  • Red blood cell transfusion dependence, defined as requiring ≥3 units of Packed red blood cells (pRBC) transfused over 16-week period in at least 2 transfusions episodes during the 16 weeks preceding randomization. Documentation of a participant's transfusion policy during this 16-week period is required.
  • A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:
  • Is a woman of non- (WONCBP). OR
  • Is a woman of childbearing potential (WOCBP) and using a method.
  • Is capable of giving signed informed consent.
  • performance status ≤2.
  • Adequate organ function.

Exclusion criteria

Exclusion criteria

  • Prior treatment with the following with noted time periods:

    1. Janus kinase (JAK)1/2 inhibitors;
    2. ACVR1 inhibitors,
    3. ACTRII receptor ligand trap other than luspatercept
    4. Hypomethylating agents or other disease modifying agents (i.e., IMiDs) and therapy for MDS
    5. ESA within 4 weeks, or 8 weeks for long-acting ESA.
    6. Growth factors (i.e., G-CSF, GM-CSF) within 4 weeks.
    7. Luspatercept within 8 weeks.
    8. agents within 4 weeks or 5 half-lives, whichever is longer.
    9. for treatment of the underlying disease within 28 days. Supportive care use of steroids for non-MDS indications may be used provided participant is on a stable dose equivalent to ≤10 mg prednisone per day.
    10. Other active anti-MDS therapy not otherwise listed within 28 days or 5 half-lives whichever is longer.
    11. Potent cytochrome P450 3A4 () inducers, except for rifampin and rifampicin, within 14 days prior to the first dose of momelotinib.
    12. Has received a within 30 days.
  • Prior or autologous stem cell transplant.
  • Has had any major surgery within 28 days prior to randomization.
  • Ongoing adverse reaction(s) from prior therapy that have not recovered to ≤Grade 1 or to the baseline status preceding prior therapy, except if the investigator, with the agreement of the sponsor, considers to be not for the tolerability of study intervention in the current clinical study.
  • MDS associated with del 5q cytogenetic abnormality.
  • MDS/ Myeloproliferative neoplasm (MPN) overlap disorders (e.g., Chronic Myelomonocytic Leukemia [CMML]).
  • Secondary MDS (i.e., MDS that is known to have arisen as the result of chemical injury, treatment with chemotherapy, and/or radiation for other diseases).
  • Known history of diagnosis of acute myeloid leukemia.
  • Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or or hereditary hemolytic anemia, gastrointestinal bleeding, or thalassemia.
  • Diagnosis of invasive or history of invasive malignancy other than the disease under study within the last 5 years, except as noted below:

    1. History of an invasive malignancy for which the participant was definitively treated, and in which the participant has been disease free for at least 2 years, and which, in the opinion of the principal investigator and medical monitor, is not expected to affect the evaluation of the effects of the study intervention on the currently targeted disease under study.
    2. Curatively treated basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, in situ cervical cancer, and/or in situ breast cancer may be enrolled.
    3. Incidental histologic finding of prostate cancer (T1a or T1b using the Tumor, nodes, [TNM] clinical staging system).
  • Uncontrolled intercurrent illness including, but not limited to:

    1. Active uncontrolled infection (participants receiving outpatient antibacterial and/or antiviral treatments for infection that is under control or as infection prophylaxis may be included in the trial); or
    2. Significant active or chronic bleeding event ≥Grade 2 per version 5.0 (CTCAE v5.0) within 4 weeks prior randomization.
    3. Uncontrolled acute and chronic liver disease (e.g., score ≥10) OR has current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis.
  • Any of the following conditions within 6 months prior to randomization:

    1. Unstable angina pectoris.
    2. Symptomatic congestive heart failure.
    3. Uncontrolled cardiac arrhythmia.
  • >480 milliseconds (msec) (corrected using Fridericia formula).
  • Psychiatric illness, social situation, or any other condition that would limit compliance with trial requirements or may interfere with the interpretation of study results, as judged by investigator or sponsor.
  • Presence of peripheral neuropathy ≥Grade 2 per CTCAE v5.0.
  • Known positive status for (HIV).
  • or C status as defined below:

    1. Active Hepatitis B infection indicated by the presence of hepatitis B surface antigen (HBsAg) at screening or within 3 months prior to the first dose of study intervention.
    2. Positive antibody test result at screening or within 3 months before the first dose of study intervention. Has any clinically significant gastrointestinal conditions or abnormalities that may alter absorption, e.g., uncontrolled nausea, vomiting, malabsorption syndrome or major resection of the stomach and/or bowels.
  • Is unable to swallow and/or retain oral medications.
  • Known or to momelotinib and its metabolites, or any of their .
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Momelotinib dose level 1

    Drug: Momelotinib

  • Experimental
    Momelotinib dose level 2

    Drug: Momelotinib

Interventions

  • Momelotinib will be administered.

    Also known as: GSK3070785

06

What researchers measure

Primary outcomes

  1. Percentage of participants with Red Blood Cells - transfusion independence (RBC-TI) for at least 12 weeks, rolling over 24 weeks

    RBC-TI defined as not requiring RBC transfusions (except in the case of clinically overt bleeding). Percentage of participants with RBC-TI will be measured for any consecutive 12-week interval over 24-week duration.

    Time frame: Up to 24 weeks

  2. Number of participants with Grade 3 Adverse events (AEs), AE leading to treatment discontinuation and AEs leading to dose modifications

    Time frame: Up to approximately 109 weeks

  3. Maximum plasma concentration (Cmax) of momelotinib and major metabolite of momelotinib (M21)

    Time frame: Up to 24 weeks

  4. Area under the plasma concentration versus time curve (AUC) of momelotinib and M21

    Time frame: Up to 24 weeks

Secondary outcomes

  1. Percentage of participants with ≥16 weeks of RBC-TI by the end of Week 24

    RBC-TI defined as not requiring RBC transfusions (except in the case of clinically overt bleeding). Percentage of participants with RBC-TI will be measured for any consecutive ≥16-week interval by the end of Week 24.

    Time frame: At week 24

  2. Percentage of participants with ≥1.5 grams per deciliter (g/dL) increase in hemoglobin

    Time frame: Up to 24 weeks

  3. Percentage of participants with ≥24 weeks of RBC-TI by the end of Week 48

    RBC-TI defined as not requiring RBC transfusions (except in the case of clinically overt bleeding). Percentage of participants with RBC-TI will be measured for any consecutive ≥24-week interval by the end of Week 48.

    Time frame: At week 48

  4. Number of participants with hematologic improvement (HI-E) response per International Working Group (IWG) 2018 criteria

    HI-E response is measured based on the combined incidence of: Low transfusion burden (LTB) patients: absence of any transfusion for ≥ 8 consecutive weeks. High transfusion burden (HTB) patients: minor response defined as reduction by ≥ 50% of red blood cell (RBC) units for ≥ 8 consecutive weeks. Major response defined as absence of RBC transfusions for ≥ 8 consecutive weeks or longer up to 24 weeks

    Time frame: Up to 24 weeks

  5. Time to RBC-TI by Weeks 24 and 48

    Time to RBC-TI defined as the time from the first dose of study intervention until the first date of TI (absence of RBC transfusion requirement).

    Time frame: Up to Weeks 24 and 48

  6. Number of participants with AEs, Serious adverse events (SAEs), AEs leading to treatment discontinuation, and AEs leading to dose modifications

    Time frame: Up to approximately 133 weeks

  7. Number of participants with AEs, SAEs, AEs leading to treatment discontinuation, and AEs leading to dose modifications by Severity

    Time frame: Up to approximately 133 weeks

  8. Number of participants with clinically significant changes in laboratory parameters

    Time frame: Up to approximately 133 weeks

  9. Number of participants with clinically significant changes in vital signs

    Time frame: Up to approximately 133 weeks

  10. Plasma concentration of momelotinib and M21

    Time frame: Up to 24 weeks

07

Study locations

39 of 39 sites recruiting
  • GSK Investigational Site
    Goodyear, Arizona 85338, United States
    Recruiting
  • GSK Investigational Site
    Duarte, California 91010-3012, United States
    Recruiting
  • GSK Investigational Site
    Irvine, California 92618, United States
    Recruiting
  • GSK Investigational Site
    New Haven, Connecticut 06519-1110, United States
    Recruiting
  • GSK Investigational Site
    Canton, Ohio 44718, United States
    Recruiting
  • GSK Investigational Site
    Houston, Texas 77030, United States
    Recruiting
  • GSK Investigational Site
    Calgary, Alberta T2N 5G2, Canada
    Recruiting
  • GSK Investigational Site
    Toronto, Ontario M5G 2M9, Canada
    Recruiting
  • GSK Investigational Site
    Le Mans, 72015, France
    Recruiting
  • GSK Investigational Site
    Nice, 06202, France
    Recruiting
  • GSK Investigational Site
    Paris, 75010, France
    Recruiting
  • GSK Investigational Site
    Poitiers, 86021, France
    Recruiting
  • GSK Investigational Site
    Toulouse, 31059, France
    Recruiting
  • GSK Investigational Site
    Münster, North Rhine-Westphalia 48149, Germany
    Recruiting
  • GSK Investigational Site
    Dresden, 01307, Germany
    Recruiting
  • GSK Investigational Site
    Leipzig, 04103, Germany
    Recruiting
  • GSK Investigational Site
    Udine, Friuli Venezia Giulia 33100, Italy
    Recruiting
  • GSK Investigational Site
    Catania, 95123, Italy
    Recruiting
  • GSK Investigational Site
    Florence, 50134, Italy
    Recruiting
  • GSK Investigational Site
    Milan, 20122, Italy
    Recruiting
  • GSK Investigational Site
    Orbassano to, 10043, Italy
    Recruiting
  • GSK Investigational Site
    Rozzano MI, 20089, Italy
    Recruiting
  • GSK Investigational Site
    Chorzów, Silesian Voivodeship 40-523, Poland
    Recruiting
  • GSK Investigational Site
    Warsaw, 02-172, Poland
    Recruiting
  • GSK Investigational Site
    Seongnam-si Gyeonggi-do, 13620, South Korea
    Recruiting
  • GSK Investigational Site
    Seoul, 03080, South Korea
    Recruiting
  • GSK Investigational Site
    Seoul, 05505, South Korea
    Recruiting
  • GSK Investigational Site
    Seoul, 06591, South Korea
    Recruiting
  • GSK Investigational Site
    Barcelona, 8035, Spain
    Recruiting
  • GSK Investigational Site
    Barcelona, 8907, Spain
    Recruiting
  • GSK Investigational Site
    Madrid, 28027, Spain
    Recruiting
  • GSK Investigational Site
    Málaga, 29010, Spain
    Recruiting
  • GSK Investigational Site
    Ourense, 32005, Spain
    Recruiting
  • GSK Investigational Site
    PamplonaNavarra, 31008, Spain
    Recruiting
  • GSK Investigational Site
    Salamanca, 37007, Spain
    Recruiting
  • GSK Investigational Site
    Valencia, 46010, Spain
    Recruiting
  • GSK Investigational Site
    Boston, PE21 9QS, United Kingdom
    Recruiting
  • GSK Investigational Site
    London, SE5 9RS, United Kingdom
    Recruiting
  • GSK Investigational Site
    Manchester, M20 4BX, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jul 2027, 25 months after the start.

Of 52 industry-sponsored phase 2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's planned 25 months is below that.

Counting every sponsor, half of 279 studies reached it within 66 months; a quarter within 40 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2025
First posted
Feb 26, 2025
StartActual
Jun 5, 2025
Primary completionEst.
Jul 14, 2027
CompletionEst.
Dec 29, 2027
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06847867
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Feb 26, 2025
Start date
Jun 5, 2025
Primary completion
Jul 14, 2027 (estimated)
Completion
Dec 29, 2027 (estimated)
Last update
Jun 2, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Momelotinib

Start the discussion